Live: Supermicro Reports Q3 Earnings Tonight. Can Strong Results Spark a Rebound?

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Mar 20, 2016 at 10:40 AM EDT

How Analysts View Valeant After an Earnings Catastrophe

Releasing preliminary results may have been ill-advised to release, as the impact was absolutely catastrophic to Valeant Pharmaceuticals stock.

Chris Lange | Mar 20, 2016 at 10:35 AM EDT

4 Key Biopharma Movers of the Past Week

Over the past week, Celator Pharmaceuticals and a few other biotech companies made impressive runs.

Chris Lange | Mar 18, 2016 at 12:40 PM EDT

Pfizer Posts Positive Late-Stage Results in Colitis Trials

Pfizer announced the results from its first two pivotal Phase 3 studies from the Oral Clinical Trials for tofacitinib in…

Lee Jackson | Mar 18, 2016 at 10:15 AM EDT

4 Well-Known Health Care Stocks Are Potential Buyout Candidates

With an aging population, and larger health care companies looking to add new technologies and capabilities, the chances for mergers…

Chris Lange | Mar 18, 2016 at 10:10 AM EDT

Why Eagle Pharma Shares Are in Free Fall

Eagle Pharmaceuticals shares were in free fall early Friday after it received a Complete Response Letter from the FDA for…

Chris Lange | Mar 17, 2016 at 1:40 PM EDT

Hutchinson China MediTech Sets Price for US IPO

Hutchinson China MediTech will offer more than 7 million American depositary shares at $13.50 apiece in and IPO valued at…

Chris Lange | Mar 17, 2016 at 9:05 AM EDT

Could This Be the Big Comeback for Vitae Pharma?

Vitae Pharmaceuticals watched its shares absolutely take off on Thursday morning following the release of positive results from its mid-stage…

Chris Lange | Mar 16, 2016 at 1:35 PM EDT

Regeneron and Sanofi Plan to Appeal Amgen Patent Verdict

Regeneron Pharmaceuticals saw its shares halted on Wednesday afternoon after a jury ruled in favor of Amgen on a cholesterol…

Chris Lange | Mar 16, 2016 at 12:50 PM EDT

4 More Key FDA Decisions in March

24/7 Wall St. has collected a few more U.S. Food and Drug Administration (FDA) decisions coming up in March.

Jon C. Ogg | Mar 16, 2016 at 11:20 AM EDT

Why One Analyst Sees Gilead Worth 66% More

Argus reiterated Gilead Sciences as Buy, but hat really matters here is that Argus has a $150 price target on…

Chris Lange | Mar 16, 2016 at 10:45 AM EDT

Bio Blast Pharma Explodes on Positive Results

Bio Blast Pharma was blowing away all the other bulls in Wednesday’s session, with its stock up over 150% on…

Chris Lange | Mar 16, 2016 at 10:05 AM EDT

Cerus Tumbles Despite FDA Approval

Shares of Cerus dropped just after the open of Wednesday’s regular trading session despite a key FDA approval.

Douglas A. McIntyre | Mar 16, 2016 at 6:47 AM EDT

Valeant CEO Michael Pearson Has to Leave

CEO Michael Pearson needs to leave Valeant Pharmaceuticals for it to have any chance to recover. The company cannot afford…

Chris Lange | Mar 15, 2016 at 12:35 PM EDT

Celator Pharma Skyrockets on Breakthrough Trial Results

Celator Pharmaceuticals has announced positive results from its Phase 3 trial of Vyxeos Liposome for Injection in patients with high-risk…

Chris Lange | Mar 15, 2016 at 11:05 AM EDT

Aeglea BioTherapeutics Prepares for IPO

Aeglea BioTherapeutics has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).

1 … 218 219 220 221 222 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

How Analysts View Valeant After an Earnings Catastrophe

4 Key Biopharma Movers of the Past Week

Pfizer Posts Positive Late-Stage Results in Colitis Trials

4 Well-Known Health Care Stocks Are Potential Buyout Candidates

Why Eagle Pharma Shares Are in Free Fall

Hutchinson China MediTech Sets Price for US IPO

Could This Be the Big Comeback for Vitae Pharma?

Regeneron and Sanofi Plan to Appeal Amgen Patent Verdict

4 More Key FDA Decisions in March

Why One Analyst Sees Gilead Worth 66% More

Bio Blast Pharma Explodes on Positive Results

Cerus Tumbles Despite FDA Approval

Valeant CEO Michael Pearson Has to Leave

Celator Pharma Skyrockets on Breakthrough Trial Results

Aeglea BioTherapeutics Prepares for IPO

Live: Supermicro Reports Q3 Earnings Tonight. Can Strong Results Spark a Rebound?

Live: Navitas Semiconductor Q1 Earnings Tonight. Can the 676% Surge Survive the Print?

Live: Arista Networks Is Reporting Q1 Earnings. Can $ANET Continue Its 32% YTD Rally?

Which Big-Box Store Chain Has Dominated 2026: Walmart, Target, or Costco?

A $360,000 Portfolio That Quietly Pays You More Than the Average Social Security Check

Jim Cramer Isn’t a Fan of Microsoft After Rough Quarter. Is He Right to Be Skeptical?

A $360,000 Portfolio That Quietly Pays You More Than the Average Social Security Check

27% of Americans Own ETFs but Allocate Just 6%, Here's Why That Costs Them Retirement Income

Live: Navitas Semiconductor Q1 Earnings Tonight. Can the 676% Surge Survive the Print?

Which Big-Box Store Chain Has Dominated 2026: Walmart, Target, or Costco?

Health and Healthcare Articles

All Health and Healthcare Articles

How Analysts View Valeant After an Earnings Catastrophe

4 Key Biopharma Movers of the Past Week

Pfizer Posts Positive Late-Stage Results in Colitis Trials

4 Well-Known Health Care Stocks Are Potential Buyout Candidates

Why Eagle Pharma Shares Are in Free Fall

Hutchinson China MediTech Sets Price for US IPO

Could This Be the Big Comeback for Vitae Pharma?

Regeneron and Sanofi Plan to Appeal Amgen Patent Verdict

4 More Key FDA Decisions in March

Why One Analyst Sees Gilead Worth 66% More

Bio Blast Pharma Explodes on Positive Results

Cerus Tumbles Despite FDA Approval

Valeant CEO Michael Pearson Has to Leave

Celator Pharma Skyrockets on Breakthrough Trial Results

Aeglea BioTherapeutics Prepares for IPO

Live: Supermicro Reports Q3 Earnings Tonight. Can Strong Results Spark a Rebound?

Live: Navitas Semiconductor Q1 Earnings Tonight. Can the 676% Surge Survive the Print?

Live: Arista Networks Is Reporting Q1 Earnings. Can $ANET Continue Its 32% YTD Rally?

Which Big-Box Store Chain Has Dominated 2026: Walmart, Target, or Costco?

A $360,000 Portfolio That Quietly Pays You More Than the Average Social Security Check

Jim Cramer Isn’t a Fan of Microsoft After Rough Quarter. Is He Right to Be Skeptical?

Featured Reads

A $360,000 Portfolio That Quietly Pays You More Than the Average Social Security Check

27% of Americans Own ETFs but Allocate Just 6%, Here's Why That Costs Them Retirement Income